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Abstract
Objective: In this study we use facility-level data from nationally representative
surveys conducted in Ghana, Kenya, and Uganda to understand pharmaceutical
availability within the three countries.
Methods: In 2012, we conducted a survey to capture information on
pharmaceuticals and other facility indicators from over 200 facilities in each country.
We analyze data on the availability of pharmaceuticals and quantify its association
with various facility-level indicators. We analyze both availability of essential
medicines, as defined by the various essential medicine lists (EMLs) of each
respective country, and availability of all surveyed pharmaceuticals deemed
important for treatment of various high-burden diseases, including those on the
EMLs.
Results: We find that there is heterogeneity with respect to availability across the
three countries with Ghana generally having better availability than Uganda and
Kenya. To analyze the relationship between facility-level factors and
pharmaceutical stock-out we use a binomial regression model. We find that the
factors associated with stock-out vary by country, but across all countries both
presence of a laboratory at the facility and presence of a vehicle at the facility are
significantly associated with reduced stock-out.
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Conclusion: The results of this study highlight the poor availability of essential
medicines across these three countries and suggest more needs to be done to
strengthen the supply system so that stock remains uninterrupted.
Introduction
Millions of people worldwide die or face disability each year due to diseases that
have proven pharmaceutical treatments [1, 2]. In order to decrease these
preventable deaths, access must increase to necessary medicines. Assuming people
visit the health center when they are sick, the provision of pharmaceuticals at the
health center to treat deadly disease is imperative. However, drugs are often not
provided at facilities due to stock-out, or specifically, a pharmaceutical not being
available due to it being out of stock. Stock-out of medicines has a profound effect
on health in various ways. First, if a drug is not available then a sick patient who
visits the health facility will not be able to receive the treatment they need. Patients
who do not receive proper drug treatment have worse outcomes. Pasquet et al.
(2010) link patients with facility-level antiretroviral medicine stock-out and find
that stock-out led to higher mortality [3]. Second, if a facility experiences stock-
out a patient may be less willing to visit the health facility because they do not
believe they will get the care and medicine they need to be properly treated.
Nabbuye-Sekandi et al. (2011) find that patients’ perceptions of a health facility
and their satisfaction with health services are directly linked to the availability of
pharmaceuticals at that facility [4]. In addition, Hanson et al. (2005) find that
availability of pharmaceuticals is a significant predictor of perceived quality of
health facilities [5]. These studies imply that as availability of pharmaceuticals
deceases, patients reduce their positive perception of the facility. Perceived quality
of a health facility can have a significant effect on a patient’s choice to utilize or
not [6]. Therefore, it is important to stock medicines so people maintain
confidence in the health system and continue to utilize it.
Despite the obvious need for drugs to treat patients, information on the
prevalence of stock-out has been predominantly analyzed through small survey
datasets and there is a dearth of information related to the determinants of stock-
out. There is a large existing literature that examines stock-out and price of
essential medicines using an approach developed by the WHO and Health
Alliance International in 2003 [7]. The approach examines the availability and
affordability of up to 50 medicines that are considered essential by the WHO. The
survey has been conducted in numerous countries worldwide and is still being
used today as a relevant policy undertaking [8–12]. Specific results from the
WHO/HAI methodology are comparable across studies. Multiple studies have
synthesized relevant data from numerous WHO/HAI surveys to generate
medicine availability estimates [13, 14]. The WHO/HAI method has been widely
used; however, it does little to take into account prevailing pharmaceutical norms
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within each country, such as different referral levels carrying different
pharmaceuticals to address their relevant burden. In addition, another limitation
of these studies is that they use surveys with small sample sizes that often lack
generalizability to the entire pharmaceutical system of a country.
Other literature has looked at pharmaceutical availability at the facility level not
using the WHO/HAI methodology. Buabeng et al. (2008) explore anti-malarial
drug availability in Ghana and find that fewer than half of the health facilities
sampled stocked the recommended first line therapy to treat malaria [15]. Despite
these numerous studies looking at availability, none of them examine the facility-
level determinants of availability.
There is some literature that examines the relationship between modifiable
policies/factors and drug availability. Kangwana et al. (2009) investigate the effect
of a nationwide pharmaceutical policy to stock artemisinin combination therapies
(ACTs) in public facilities in Kenya [16]. They find uptake of the policy has been
widespread; however, stock-out of artemether-lumefantrine is high, greater than
25%, two years after its introduction as a treatment for uncomplicated malaria.
Davis et al. (2013) analyze availability and affordability of ACTs in five countries
currently receiving Global Fund funding [17]. They find that stock-out is higher
among rural facilities than urban in Ghana and Kenya and that stock-out rates
were highest in rural Kenya (87% experienced at least one stock-out occurrence in
the prior 3 months) and lowest in Tanzania (20.4%). Tumwine et al. (2010)
analyze pharmaceutical stock-out in a single hospital in southwestern Uganda
using a pre/post design. During the pre-period the hospital used a push system in
which the facility was sent a package of drugs determined by the government and
in the post-period it used a pull system in which the facility ordered its own drugs
based on need [18]. They find that the hospital faced significantly higher stock-
out while under a push system, but they acknowledge the limitations inherent in
examining a single facility.
The need for increased access to pharmaceuticals drove the World Health
Organization to publish its first essential drugs list in 1977, which later became the
essential medicines list (EML) and is now on its 18th edition [19, 20]. The EML is
designed to highlight drugs that are essential to the care of diseases that plague
individuals worldwide. The EML has become a ubiquitous concept with many
countries adopting the strategy of creating national EMLs to treat their relative
disease burdens in cost-effective ways. Ghana, Kenya, and Uganda have all
developed EMLs and the pharmaceuticals included in each vary slightly depending
on the country’s needs [21–23]. The national EMLs are designed to include the
pharmaceuticals that should be available to treat disease at various levels of the
public health care system. For example, a referral hospital should carry specialist
medicines that are necessary for care at the national level, but at the local level
only a few select pharmaceuticals may be available to treat the most common
diseases. Private facilities are not required to carry the essential medicines laid out
by the national EML guidelines, but many do given their pertinence and cost-
effectiveness.
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In this study we utilize large nationally representative facility-level datasets to
provide new estimates of pharmaceutical availability in three sub-Saharan African
countries— Ghana, Kenya, and Uganda —and thus fill some of the existing
knowledge gap on availability in the region. To our knowledge, this study is the
first to examine the relationship between supply chain and facility-level factors
and stock-out using nationally representative facility datasets.
Methods
Data
Data was collected using a standard survey instrument in each country as part of
the Access, Bottlenecks, Cost and Equity (ABCE) project [24–26]. Field work was
conducted in Kenya and Uganda from May to November of 2012 and in Ghana
from June to September of 2012. A nationally representative sample of health
facilities and pharmacies were visited in each country. Data on pharmaceuticals
was collected from 209 facilities in Kenya, 220 facilities in Ghana and 230 facilities
in Uganda. Facilities were grouped based on their ability to provide service and
their designation by the various Ministries of Health in each country. We have
labeled these groups of facilities as platforms and will report on them as such.
Information on the facilities and platforms is summarized in Table 1. The ABCE
study was reviewed and approved by the University of Washington’s Institutional
Review Board and the corresponding Institutional Review Boards in Ghana,
Kenya, and Uganda.
Questions on specific pharmaceuticals varied slightly in each country based on
country data needs, but a core group of 50 pharmaceuticals were asked about
across all countries. Pharmaceuticals were included based on their necessity for
treating high-burden diseases and on advice from our in-country partners. The
vast majority of pharmaceuticals were from the EML of each country.
In addition to pharmaceutical data captured at the facility, various facility
characteristics were asked about in the survey. Questions asked varied by country,
but Table 2 summarizes the responses. Specifically, questions about the
storekeeper were not asked in Ghana, whereas questions about where the facility
regularly receives pharmaceuticals from were not asked in Kenya. Distances were
calculated using straight line distance to the capital.
The dependent variable in the regressions was the number of pharmaceuticals
that were stocked-out. Each drug was categorized as stocked-out if it was not
available at the time of survey administration. In order for a pharmaceutical to be
considered available at the time of survey administration, the drug had to be
directly observed by the surveyor. General pharmaceuticals in all facilities were
considered stocked-out if the facility reported normally having the drug but it was
not directly observed. Essential medicines were considered stocked-out if the
facility was public—thus having to adhere to the EML guidelines—and the drug
was unavailable, even if they reported not typically carrying the drug. This
Pharmaceutical Availability in Ghana, Kenya, and Uganda
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specification creates higher drug stock-out since drugs not reported as typically
carried are considered stocked-out.
Statistical analysis
The data was structured so that each facility had a number of drugs stocked-out
and a bounded number of possible drugs stocked, as well as various facility-level
variables. The data structure led us to analyze the association between facility
characteristics and pharmaceutical stock-out using a generalized linear model
with a binomial family. Two different dependent variables were used, 1)
pharmaceutical stock-out of any drug in all facilities and 2) pharmaceutical stock-
out of essential medicines in public facilities. Independent variables were included
where appropriate for each country. Specifically, whether or not the facility was on
Table 1. Pharmaceutical availability by country.
All pharmaceuticals Essential Medicines
Platform
Number of
facilities
Mean number
stocked out at
time of survey %
# of drugs
available
Mean EML
drugs stocked
out %
Total EML
drugs
expected
Ghana Referral hospital 11 5.2 12% 44 11.5 24% 48
Public hospital 18 2.3 6% 38 13.4 29% 46
Health center 43 2.0 9% 22 4.7 26% 18
Private clinic 30 2.8 10% 29
Community health post 65 2.4 15% 16 2.5 35% 7
Maternity clinic 16 2.5 11% 23
Pharmacy 37 2.0 8% 27
Kenya Referral hospital 11 3.0 7% 41 7.6 18% 42
District hospital 19 4.3 12% 37 10.8 26% 42
Private hospital 17 2.9 7% 41
Sub-district hospital 9 6.1 17% 35 7.8 29% 27
Health centre 54 6.6 23% 28 8.7 33% 26
Medical clinic 18 4.0 11% 38
Dispensary 34 5.3 22% 24 10.3 39% 26
Maternity clinic 20 2.6 9% 29
Pharmacy 16 1.9 5% 40
VCT center 11 0.2 5% 4
Uganda Referral hospital 13 5.5 12% 46 11.2 22% 51
District hospital 21 3.8 9% 43 12.4 25% 50
Private hospital 6 1.8 4% 47
Health center IV 39 6.8 17% 39 14.1 33% 43
Health center III 54 6.6 21% 31 11.1 37% 30
Medical clinic 14 2.8 8% 35
Health center II 46 5.7 24% 24 6.6 36% 18
Pharmacy 37 2.7 7% 38
doi:10.1371/journal.pone.0114762.t001
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a push or pull system was included as a categorical variable coded as push, pull or
both. We included whether or not the facility had an administrative person, an
accountant, a medical personnel or a pharmacist in charge of monitoring
pharmaceuticals. The presence of different types of record keepers were included
as binary variables. Whether or not the facility received drug kits, whether or not
the facility had a lab, and whether or not the facility had access to a vehicle were
included as binary variables. Rurality of the facility was included as a categorical
variable, with rural, semi-urban and urban as the three categories. Distance to the
capital was coded as a continuous variable and the unit of analysis was the decimal
degree. Decimal degrees were measured to the hundredth of a degree. Since all
countries are at or near the equator, we found the variability in actual distance to
be small enough for this to be a suitable distance measure. Whether or not a
facility received pharmaceuticals from the Ministry of Health or received them
from a private provider were each included as binary variables. In addition to the
covariates measured at the facility level, we also controlled for platform of the
facility and month that the facility survey took place—to control for potential
seasonality of stock-out. Facilities were not included in the regression analysis if
they reported not carrying any of the pharmaceuticals asked about in the survey.
This accounted for 13 facilities (9 in Kenya, 1 in Uganda, and 3 in Ghana) when
using the any drug dependent variable. No public facilities were dropped in the
analysis of EML drugs since all were expected to carry the essential drugs.
Regression analysis was done using the binreg command in Stata software version
12 and a logit link function was used to define the relationship between the
independent variables and stock-out [27]. Standard errors were corrected for
heteroskedasticity using White’s general correction, implemented as the robust
option in Stata.
Table 2. Facility level characteristics by country.
Uganda Kenya Ghana Range
Order drugs and receive routine shipments 10% 19% 19% [0,1]
Order drugs only 63% 74% 75% [0,1]
Receive routine shipments only 26% 6% 5% [0,1]
Receive drugs from the Ministry of Health 40% 13% [0,1]
Receive drugs from the private market 60% 95% [0,1]
Record keeper: admin personnel 11% 11% [0,1]
Record keeper: medical personnel 41% 36% [0,1]
Record keeper: pharmaceutical personnel 46% 48% [0,1]
Record keeper: accounting personnel 10% 7% [0,1]
Facility has a vehicle 59% 49% 67% [0,1]
Facility has drug kits 42% 39% 0% [0,1]
Facility has a lab 73% 84% 56% [0,1]
Distance to the capital in decimal degrees 1.57 1.72 2.43 [0,5.7]
doi:10.1371/journal.pone.0114762.t002
Pharmaceutical Availability in Ghana, Kenya, and Uganda
PLOS ONE | DOI:10.1371/journal.pone.0114762 December 11, 2014 6 / 12
Results
Availability of pharmaceuticals
Table 1 summarizes the stock-out variable by country and platform. Results
indicate that rates of pharmaceutical stock and stock-out varied by country and
platform. In general, facilities carried more pharmaceuticals the more complex the
services they offered. Hospitals tended to carry over 80% of the pharmaceuticals
surveyed, while community level facilities carried less than half. CHPS
compounds in Ghana carried the fewest drugs on average per facility with 16 of
the 54 surveyed pharmaceuticals typically available. All three countries faced
similar patterns of stock-out with the low-level community public health facilities
facing the highest proportion of drugs stocked-out. Pharmacies faced very low
stock-out in all three countries. In addition, private medical service providers,
such as private hospitals and medical clinics, faced low stock-out compared to
their public counterparts.
Certain high-profile pharmaceuticals are of significant importance to address
the disease burden of these sub-Saharan African countries. Table 3 summarizes
stock-out of a country’s first line treatment for malaria, pneumonia, and
meningitis. In general, stock-out of antimalarial drugs was lower than drugs to
treat pneumonia and meningitis. Across the sample, Ghana had the lowest rate of
ACT stock-out with only 2% of facilities and Kenya the highest with 7%.
Amoxicillin stock-out was also much lower in Ghana, at 5% compared with over
14% in Uganda and 21% in Kenya. All countries faced stock-out rates greater or
equal to 10% for ceftriaxone and chloramphenicol, the drugs necessary to treat
meningitis.
Determinants of stock-out
The results of the country specific regressions suggest that the factors influencing
stock-out differ across the three countries (Table 4). Rurality of the facility did
not have a significant effect on stock-out of essential medicines in any of the
countries. However, in Uganda rural facilities had 59% higher odds of stock-out
than urban facilities, while in Kenya rural facilities had 72% lower odds of stock-
out than urban, but it was only marginally significant. In Ghana, if the facility
received drugs from a private supplier they were less likely to face stock-out of any
medication and essential medications. In Uganda, both facilities receiving
pharmaceuticals from the MOH and from private suppliers were associated with
reduced stock-out. In Uganda, presence of a vehicle was associated with lower
stock-out for both any surveyed drug and essential medicines. In Ghana and
Kenya the results were similar, with presence of a vehicle associated with lower
stock-out; however, the effect was only significant for essential medicines. Having
a lab in the facility was significantly associated with reduced essential medicine
stock-out, possibly suggesting that more advanced facilities are able to test and
subsequently treat only positive cases, which would drive down unnecessary use of
Pharmaceutical Availability in Ghana, Kenya, and Uganda
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pharmaceuticals. Where the facility received drugs from was significantly
associated with stock-out.
Discussion
In this analysis of over 600 health facilities in Ghana, Kenya, and Uganda we have
shown that pharmaceutical stock-out is still a persistent problem despite large
efforts in each country to strengthen the provision of pharmaceuticals. Availability
of essential medicines was strikingly low, with over 30% of those expected to be
available not at the facility. Even if availability is low, it is important to note that
facility specific stock-out does not necessarily imply that a patient does not receive
pharmaceuticals. A patient could go to a private pharmacy or another provider to
get medication. However, this entails multiple trips by the patient and as the
number of required trips increases, the likelihood a patient will visit the
subsequent facility decreases, thus decreasing their probability of getting the
pharmaceuticals they need. This has the potential to have a profound impact on
the health of these populations if patients are not receiving the pharmaceuticals
they need. It is necessary that facilities carry the pharmaceuticals expected of them
so that patients get the care they need and expect.
Regression analysis suggests the presence of vehicles at the facility is associated
with reduced stock-out. One potential way to alleviate stock-out in Ghana, Kenya,
and Uganda is to provide vehicles to facilities so they can seek out medications
when their stock is low. This intervention would give the facility more autonomy
and accountability in dealing with pharmaceutical procurement. Despite our a
priori hypothesis that presence of pharmacists would reduce stock-outs, we found
no evidence that this was the case. Furthermore we found that there were no
significant differences in stock-out based on who was in charge of the
pharmaceutical records. This finding implies that facilities without experienced
pharmaceutical personnel may still be capable of monitoring their own stock.
Table 3. Stock-out of essential medicines to treat malaria, pneumonia and meningitis by country.
Uganda Kenya Ghana
Drug % Count % Count % Count
Coartem 6% 226 7% 194 6% 204
AS+AQ 14% 199
Any ACT 6% 226 7% 194 2% 214
Amoxicillin 14% 225 21% 198 5% 205
Cotrimoxizole 4% 227 6% 195 5% 200
Erthromycin 31% 207 30% 182 15% 136
Chloramphenicol 14% 216 27% 123 10% 166
Ceftriaxone 14% 149 31% 162 10% 99
Notes: Percent is rate of stock-out. Count is the number of facilities that said they typically carry the drug. AS+AQ
stands for Artesunate + Amodiaquine.
doi:10.1371/journal.pone.0114762.t003
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Given this outcome, supplying vehicles to facilities, even those without a
pharmacist, would be a useful intervention.
The results from our analysis on availability were consistent with those found in
the existing literature. Robertson et al. (2009) found the rate of pharmaceutical
availability in our surveyed countries to be lowest in Ugandan district hospitals
and primary health care centers, each at 29% [28]. We found availability to be
Table 4. Generalized linear model results of pharmaceutical stock-out in Uganda, Kenya and Ghana.
Uganda Kenya Ghana
Dependent variable ALL EML ALL EML ALL EML
Both routine and order Base Base Base Base Base Base
Routine only 0.73 0.80 1.24 1.13 0.92 1.26
(0.16) (0.12) (0.26) (0.15) (0.17) (0.23)
Order only 0.65* 0.65** 0.92 0.91 2.18** 1.62
(0.16) (0.11) (0.30) (0.20) (0.73) (0.68)
Receive drugs from the MOH 0.75* 0.77** 0.73 1.01
(0.13) (0.09) (0.19) (0.16)
Receive drugs from private 0.71 0.75** 0.50*** 0.34***
(0.17) (0.10) (0.13) (0.12)
Record keeper-admin 0.57 0.49* 0.78 1.10
(0.23) (0.19) (0.28) (0.38)
Record keeper-medical 0.85 0.97 0.54 0.76
(0.25) (0.25) (0.21) (0.29)
Record keeper-pharmacist 0.76 0.85 0.61 0.89
(0.25) (0.22) (0.22) (0.34)
Record keeper-accountant 0.98 0.83 0.75 1.05
(0.37) (0.31) (0.25) (0.53)
Presence of a vehicle 0.74* 0.81* 0.75 0.68*** 0.98 0.80
(0.13) (0.10) (0.14) (0.09) (0.20) (0.14)
Facility receives drug kits 1.20 1.02 1.04 0.86
(0.17) (0.10) (0.22) (0.12)
Presence of a lab 0.81 0.73** 0.76 0.57*** 0.84 0.72**
(0.18) (0.10) (0.27) (0.11) (0.17) (0.10)
Urban Reference Reference Reference Reference Reference Reference
Semi-urban 1.09 0.94 1.04 0.87 1.24 1.22
(0.19) (0.12) (0.21) (0.12) (0.32) (0.21)
Rural 1.59** 1.07 0.58* 1.15 0.71 1.08
(0.31) (0.17) (0.17) (0.20) (0.15) (0.22)
Distance to capitol 1.07 1.00 1.01 1.12** 1.09* 1.03
(0.12) (0.08) (0.07) (0.05) (0.05) (0.04)
N 227 150 186 114 217 137
Notes: Coefficients are odds ratios. Robust standard errors are included in parentheses. Dependent variable ALL implies regression was run with all drugs
included in the regression model. Dependent variable EML implies the regression was only run on public facilities and only on EML drugs. *,**, and ***
denote significance at the 0.1,0.05, and 0.01 level respectively. Regressions also controlled for facility type and the month of survey but results are not
shown.
doi:10.1371/journal.pone.0114762.t004
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much higher, which could be due to the Robertson study using specific
formulations of the drug, rather than asking about the drug regardless of
formulation, as we did. In addition, the Robertson study uses a standard 20
medicines across 14 different African countries and did not incorporate whether
Uganda utilizes those 20 medicines. Davis et al. (2013) find stock-out rates of
ACTs among our surveyed countries to be highest in Kenya and lowest in Ghana
[17]. Although their stock-out measure is not directly comparable because it
incorporates any stock-out within the past 3 months rather than at the time of
survey, their results seem to show a similar trend. Our analysis provides more
robust results because we analyzed more drugs and used directly observed
availability rather than self-reported availability.
This analysis faced three specific limitations. First, in our survey we did not ask
about availability of specific formulations of a pharmaceutical. If we had
information on this we would be better able to assess the importance of some
drugs over others. For example, a facility carrying an antibiotic for use with
pediatric patients would still be considered not having stocked-out of that
antibiotic even if the antibiotic for adults was stocked-out. However, the
likelihood that this limitation would have any real effect on the analysis is
minimal since it is likely that facilities stock pharmaceutical formulations that are
prescribed to them by the EML and not others. Second, we did not measure if the
drug was effective. Counterfeit drugs are known to exist in Africa but very little is
known about their prevalence due to lack of survey data [29, 30]. We attempted to
increase the probability of correctly classifying drugs by ensuring that our trained
RAs directly observed the pharmaceuticals during survey administration. Future
analysis should focus on determining, in addition to if a facility stocks medicines,
if the medicines they stock are effective and safe. Third, we did not have outcomes
at the patient level and therefore were unable to assess the relationship between
pharmaceutical stock-out and patient outcomes. Although it is not exactly
relevant as a limitation of the analysis presented in this study, it is an area we
would like to explore with more rich datasets that link facility pharmaceutical
availability with patient outcomes data.
Conclusion
Very little existing literature has explored the relationship between facility-level
determinants and availability of pharmaceuticals. Future research should attempt
to better understand the causal mechanisms that drive pharmaceutical procure-
ment and subsequent stock-out. In addition, countries should take a close look at
their own health systems to understand where the need exists for better
pharmaceutical monitoring to improve drug availability.
In conclusion, Ghana, Kenya, and Uganda still have a long road ahead before
necessary essential medicines are available in the health facilities as they are
mandated. Investment should be made to strengthen the monitoring system of
pharmaceutical procurement and more autonomy should be given to facilities to
Pharmaceutical Availability in Ghana, Kenya, and Uganda
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monitor their stock. With increased availability of essential medicines the health
of these countries should improve.
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